Physician profile
Sherif Malek
NPI 1699716175
$13,268.51
in general payments reported to CMS, 2019-2025
51 companies · $1,923 in 2025
The $1,923 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,772 · 2020: $1,131 · 2021: $2,105 · 2022: $2,078 · 2023: $2,446 · 2024: $1,814 · 2025: $1,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,183.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,975.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,516.34 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,460.03 | 2021-2025 | |
| Amgen INC. | $945.93 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $921.66 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $577.75 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $529.45 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $409.61 | 2019-2023 | Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $406.03 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $354.09 | 2019-2025 | Jardiance, Amyvid, Emgality |
| Pfizer INC. | $315.21 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $261.01 | 2022-2025 | |
| Corcept Therapeutics | $255.16 | 2024-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $209.91 | 2019-2025 | |
| Eisai INC. | $200.40 | 2019-2024 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherif Malek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.